PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	09/180,657
Filing Date	November 12, 1998
First Named Inventor	
Art Unit	1644
Examiner Name	Nolan, Patrick J.
Attorney Docket Number	021385-014500US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]	Foreign Patent Document: Number[4]	Foreign Patent Document: Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
PN	AA	AU	29906/92		10-06-93	Commonwealth Scientific and Industrial Research Organisation		☐

Examiner Signature	Pat Nol	Date Considered	5/19/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] **Applicant's** unique citation designation number **(optional)**. [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	09/180,657
Filing Date	November 12, 1998
First Named Inventor	
Art Unit	1644
Examiner Name	Nolan, Patrick J.
Attorney Docket Number	021385-014500US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
PN	AB	ALEXANDER, DENIS, et al; Five Related Lebanese Individuals with High Plasma Lysosomal Hydrolases: A New Defect in Mannose-6-Phosphate Receptor Recognition?; *American Journal of Human Genetics*; 1984; pp. 1001-1014; Vol. 36, No. 5	
	AC	BROOKS, D.A., et al.; Immunoquantification of the Low Abundance Lysosomal Enzyme *N*-Acetylgalactosamine 4-Sulphatase; *Journal of Inherited Metabolic Disease;* 1990; pp. 108-120; Vol. 13, No. 1	
	AD	GATTI, R., et al.; Comparative Study of 15 Lysosomal Enzymes in Chorionic Villi and Cultured Amniotic Fluid Cells. Early prenatal diagnosis in seven pregnancies at risk for lysosomal storage diseases; *Prenatal Diagnosis*; September 1985; pp. 329-336; Vol. 5, No. 5	
	AE	GRIFFITHS, PENELOPE A., et al.; Plasma Acid Hydrolases in Normal Adults and Children, and in Patients with Some Lysosomal Storage Diseases; *International Journal of Clinical Chemistry*; 1 December 1978; pp. 129-141; Vol. 90, No. 2	
	AF	GUO, YUFENG, et al; Elevated plasma chitotriosidase activity in various lysosomal storage disorders; *Journal of Inherited Metabolic Disease;* 1995; pp. 717-722; Vol. 18, No. 6	
	AG	KLEIMAN, FRIDA, E., et al.; Sandhoff disease in Argentina: high frequency of a splice site mutation in the HEXB gene and correlation between enzyme and DNA-based tests for heterozygote detection; *Human Genetics*; 1994; pp. 279-282; Vol. 94	
	AH	LOVELL, KATHRYN L., et al.; Biochemical and Histochemical Analysis of Lysosomal Enzyme Activities in Caprine β-Mannosidosis; *Molecular and Chemical Neuropathology*; 1994; pp. 61-74; Vol. 21, No. 1	
	AI	McCABE, NORAH R., et al.; Preferential Inhibition of Lysosomal Beta-Mannosidase by Sucrose; *Enzyme*; 1990; pp. 137-145; Vol. 43, No. 3	
	AJ	O'BRIEN, JOHN S., et al.; Saposin proteins: structure, function, and role in human lysomomal storage disorders; *FASEB J.*; 1991; pp. 301-308; Vol. 5	
	AK	PRENCE ELIZABETH M., et al.; Diagnosis of α-Mannosidosis by Measuring α-Mannosidase in Plasma; *Clinical Chemistry*; 1992; pp. 501-503; Vol. 38, No. 4	
	AL	WHITLEY, CHESTER B., et al.; Long-Term Outcome of Hurler Syndrome Following Bone Marrow Transplantation; *American Journal of Medical Genetics;* 15 April 1993; pp. 209-218; Vol. 46, No. 2	
	AM	YAMAGUCHI, KEIKO; Improvement of Tear Lysosomal Enzyme Levels after Treatment with Bone Marrow Transplantation in a Patient with I-Cell Disease; *Ophthalmic Research;* 1989; pp. 226-229; Vol. 21, No. 3	

Examiner Signature	PN	Date Considered	5/19/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.